Mobilizace hematopoetických buněk u pacientů s mnohočetným myelomem - srovnání 3 možností stimulačních režimů

KREJČÍ, Marta, Roman HÁJEK, Zdeněk KOŘÍSTEK, Andrea KŘIVANOVÁ, M. NAVRÁTIL and Zdeněk ADAM. Mobilizace hematopoetických buněk u pacientů s mnohočetným myelomem - srovnání 3 možností stimulačních režimů (Haematopoietic stem cell mobilization in patients with multiple myeloma-comparison of 3 variations of the stimulating regime). Vnitřní lékařství. Praha: Česk lékařská společnost J. Ev. Purkyně, 2000, vol. 46, No 8, p. 439-443. ISSN 0042-773X.

Basic information

• Original name: Mobilizace hematopoetických buněk u pacientů s mnohočetným myelomem - srovnání 3 možností stimulačních režimů
• Name (in English): Haematopoietic stem cell mobilization in patients with multiple myeloma-comparison of 3 variations of the stimulating regime
• Authors: KREJČÍ, Marta (203 Czech Republic, guarantor), Roman HÁJEK (203 Czech Republic), Zdeněk KOŘÍSTEK (203 Czech Republic), Andrea KŘIVANOVÁ (203 Czech Republic), M. NAVRÁTIL (203 Czech Republic) and Zdeněk ADAM (203 Czech Republic).
• Edition: Vnitřní lékařství, Praha, Česk lékařská společnost J. Ev. Purkyně, 2000, 0042-773X.

Other information

• Original language: Czech
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• Organization unit: Faculty of Medicine
• Keywords (in Czech): mnohočetný myelom
• Keywords in English: multiple myeloma; haematopoetic stem cells
• Tags: haematopoetic stem cells, multiple myeloma

Abstract

V článku jsou popisovány různé stimulační faktory na hematopoetické buňky.

Abstract (in English)

In the literature various regimes are described for successful collection of haematopoietic stem cells in patients with multiple myeloma. Most frequently cyclophosphamide is used, 5 g/m2 combined with different doses of haematopoietic growth factors. In our group the yields and tolerance of three stimulating regimes are compared: 1. cyclophosphamide 5 g/m2 and filgrastim (G-CSF) 5 micrograms/kg 2. cyclophosphamide 5 mg/m2 and filgrastim 10 micrograms/kg 3. cyclophosphamide 5 g/m2 and figrastim 5 micrograms/kg along with erythropoitin 50 IU/kg. Cyclophsphamide is administered always on the first day and the haematopoietic growth factors then from the third day till the end of collection of haematopoitic cells. In patients with multiple myeloma where only four cycles of VAD chemotherapy preceded and where radiotherapy of the axial skeleton was not used, optimal collection of haematopoietic stem cells was achieved after administration of cyclohosphamide 5 g/m2 with subsequent administration of 5 micrograms/kg G-CSF. By increasing the dose of G-CSF to 10 micrograms/kg or adding 50 IU/kg erthropoietin did not lead to a significant improvement of the tolerance and yield of this procedure.